References
Akinyemi, K. O., B. S. Bamiro and A. O. Coker, 2007: Salmonellosis in
Lagos, Nigeria: incidence of Plasmodium falciparum-associated
co-infection, patterns of antimicrobial resistance, and emergence of
reduced susceptibility to fluoroquinolones. Journal of health,
population, and nutrition, 25, 351-358.
Brink, A. J., 2019: Epidemiology of carbapenem-resistant Gram-negative
infections globally. Current opinion in infectious diseases, 32,
609-616.
CLSI, 2011: Clinical and Laboratory Standards Institute. Performanc
Standardsfor Antimicrobial Susceptibility Testing. Nineteenth
Informational Supplement. CLSI document M100-S21. Wayne, PA, USA.
Falagas, M. E., D. E. Karageorgopoulos and P. Nordmann, 2011:
Therapeutic options for infections with Enterobacteriaceae producing
carbapenem-hydrolyzing enzymes. Future microbiology, 6, 653-666.
Founou, L. L., R. C. Founou, M. Allam, A. Ismail, C. F. Djoko and S. Y.
Essack, 2018: Genome Sequencing of Extended-Spectrum beta-Lactamase
(ESBL)-Producing Klebsiella pneumoniae Isolated from Pigs and Abattoir
Workers in Cameroon. Frontiers in microbiology, 9, 188.
Hertz, F. B., F. Jansaker, K. O. Okon, I. S. Abdulmumin, J. O. Onah, J.
Ladan and J. D. Knudsen, 2019: ESBL-production in Escherichia
coli and Klebsiella pneumoniae isolates from Nigeria.MicrobiologyOpen, 8, e00816.
Landman, D., J. K. Salvani, S. Bratu and J. Quale, 2005: Evaluation of
techniques for detection of carbapenem-resistant Klebsiella pneumoniae
in stool surveillance cultures. Journal of clinical microbiology,43, 5639-5641.
Muller-Schulte, E., M. N. Tuo, C. Akoua-Koffi, F. Schaumburg and S. L.
Becker, 2019: High prevalence of ESBL-producing Klebsiella
pneumoniae in clinical samples from central Cote d’Ivoire.International journal of infectious diseases: IJID: official
publication of the International Society for Infectious Diseases .
Obasi, A., S. Nwachukwu, E. Ugoji, C. Kohler, A. Gohler, V. Balau, Y.
Pfeifer and I. Steinmetz, 2017: Extended-Spectrum
beta-Lactamase-Producing Klebsiella pneumoniae from
Pharmaceutical Wastewaters in South-Western Nigeria. Microbial
drug resistance (Larchmont, N.Y.), 23, 1013-1018.
Olalekan, A., F. Onwugamba, B. Iwalokun, A. Mellmann, K. Becker and F.
Schaumburg, 2019: High proportion of carbapenemase producing
Escherichia coli and Klebsiella pneumonia e among extended
spectrum beta-lactamase producers in Nigerian hospitals. Journal
of global antimicrobial resistance .
Pai, H., S. Lyu, J. H. Lee, J. Kim, Y. Kwon, J. W. Kim and K. W. Choe,
1999: Survey of extended-spectrum beta-lactamases in clinical isolates
of Escherichia coli and Klebsiella pneumoniae : prevalence
of TEM-52 in Korea. Journal of clinical microbiology, 37,
1758-1763.
Phillips, I., 1993: Cowan and Steel’s Manual for the Identification of
Medical Bacteria. J Clin Pathol, 46, 975-975.
Raji, M. A., W. Jamal, O. Ojemhen and V. O. Rotimi, 2013:
Point-surveillance of antibiotic resistance in Enterobacteriaceaeisolates from patients in a Lagos Teaching Hospital, Nigeria.Journal of infection and public health, 6, 431-437.
Ranjbar, R., A. Fatahian Kelishadrokhi and M. Chehelgerdi, 2019:
Molecular characterization, serotypes and phenotypic and genotypic
evaluation of antibiotic resistance of the Klebsiella pneumoniaestrains isolated from different types of hospital-acquired infections.Infection and drug resistance, 12, 603-611.
Rossolini, G. M., 2015: Extensively drug-resistant
carbapenemase-producing Enterobacteriaceae : an emerging challenge
for clinicians and healthcare systems. Journal of internal
medicine, 277, 528-531.
Sturenburg, E., A. Kuhn, D. Mack and R. Laufs, 2004: A novel
extended-spectrum beta-lactamase CTX-M-23 with a P167T substitution in
the active-site omega loop associated with ceftazidime resistance.The Journal of antimicrobial chemotherapy, 54, 406-409.
Yigit, H., A. M. Queenan, G. J. Anderson, A. Domenech-Sanchez, J. W.
Biddle, C. D. Steward, S. Alberti, K. Bush and F. C. Tenover, 2001:
Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a
carbapenem-resistant strain of Klebsiella pneumoniae.Antimicrobial agents and chemotherapy, 45, 1151-1161.
Table 1: Numbers and types of collected samples and K.
pneumoniae positive isolates that have been used in the current study
distributed in relation to the source of sampling.